CASE REPORT
Hypersensitivity reaction against influenza vaccine in a patient with rheumatoid arthritis after the initiation of etanercept injections
Authors
Takashi Kato1,2, Akiko Kiire1,2, Hazime Yamagata2, Hisashi Yamanaka1 and Naoyuki Kamatani1
| (1) |
Institute of Rheumatology, Tokyo Women's Medical University, 10-22 Kawada-cho, Shinjuku-ku, Tokyo 162-0054, Japan |
| (2) |
Division of Internal Medicine, Murayama Medical Center, Musashimurayama, Japan |
Received:
27 April 2006
Accepted:
29 June 2006
Full Text
> Click Here （member's only）
Abstract
A 58-year-old Japanese woman with rheumatoid arthritis (RA) suffered from high fever triggered by administration of an influenza vaccine after a 4-month-long effective treatment course with the TNF-α inhibitor etanercept. Influenza vaccine had been previously administrated safely to the patient before initiation of etanercept therapy. The fever occurred without other symptoms soon after vaccine administration, progressed to high fever 1 day later, and spontaneously resolved the second day. The clinical course appears to be compatible with drug fever closely associated with immediate hypersensitivity (in particular, late-phase type I allergic reaction), in which T helper (Th) 2 cells play a crucial role. Etanercept can strongly suppress Th1-mediated reactions; therefore, Th2 activity may be augmented by etanercept treatment in aspect of antagonism between Th1 and Th2 mechanisms. In RA patients who receive treatment with TNF-α inhibitor such as etanercept, activation of Th2-mediated immune responses such as immediate hypersensitivity may be a necessary side effect for those who receive vaccinations.
Key words
Etanercept - Hypersensitivity - Influenza vaccine - Rheumatoid arthritis (RA) - T helper (Th) 1 - T helper (Th) 2 |
